There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ACADIA Pharmaceuticals (ACAD) and Evolus (EOLS) with bullish sentiments.
ACADIA Pharmaceuticals (ACAD)
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on ACADIA Pharmaceuticals today and set a price target of $60.00. The company’s shares closed last Monday at $45.84.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 14.5% and a 50.3% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Proteostasis Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for ACADIA Pharmaceuticals with a $59.30 average price target.
See today’s analyst top recommended stocks >>
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Evolus today and set a price target of $34.00. The company’s shares closed last Monday at $10.29, close to its 52-week low of $9.20.
According to TipRanks.com, Tsao is a 5-star analyst with an average return of 12.0% and a 53.9% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Minerva Neurosciences, and Amag Pharmaceuticals.
Currently, the analyst consensus on Evolus is a Strong Buy with an average price target of $28.83, which is a 188.0% upside from current levels. In a report issued on February 5, Mizuho Securities also initiated coverage with a Buy rating on the stock with a $20.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on EOLS: